ReviewPaediatric drugs2014
Omalizumab in children.
Review in Paediatric drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Systematic review and meta-analysis of omalizumab for IgE-mediated food allergy in children and young adults.Frontiers in immunology · 2025Pooled it
- Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses.The European respiratory journal · 2024Guideline
- Effect of vitamin D supplementation on total and allergen-specific IgE in children with asthma and low vitamin D levels.The Journal of allergy and clinical immunology · 2022Trial
- Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.Current allergy and asthma reports · 2026Review
- Biologic therapies for severe pediatric asthma: efficacy, safety, and biomarker-guided selection.Frontiers in allergy · 2026Review
- [Clinical features and immunotherapy for children with loss-of-function/gain-of-function mutations in theZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- Biomarkers for Short-Term Omalizumab Response in Chronic Spontaneous Urticaria.Annals of dermatology · 2024Article
- Omalizumab may protect allergic patients against COVID-19: A systematic review.The World Allergy Organization journal · 2023Review
- An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics.Medicina (Kaunas, Lithuania) · 2022Review
- Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review.Biologics : targets & therapy · 2021Review
- Case Report: Self-Administration of Omalizumab in an Adolescent With Severe Asthma During SARS-CoV-2 Infection.Frontiers in pediatrics · 2021Article
- Biologics to Treat Severe Asthma in Children and Adolescents: A Practical Update.Pediatric allergy, immunology, and pulmonology · 2020Review
- Urticaria in childhood.Acta bio-medica : Atenei Parmensis · 2020Article
- Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View.Children (Basel, Switzerland) · 2020Review
- Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology.Clinical and molecular allergy : CMA · 2020Review
- Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?Italian journal of pediatrics · 2019Review
- Eosinophilic esophagitis in children: doubts and future perspectives.Journal of translational medicine · 2019Review
- Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives.Paediatric drugs · 2019Article
- Food Allergies: Current and Future Treatments.Medicina (Kaunas, Lithuania) · 2019Review
- [Age-specific aspects in the treatment of angioedema patients].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of circulating immunoglobulin E (IgE) and expression of IgE high-affinity receptors on mast cells and basophils, interrupting the subsequent allergic inflammatory cascade. Current indications for treatment with omalizumab in pediatric patients are clearly defined and are confined to moderate-to-severe uncontrolled allergic asthma and chronic spontaneous urticaria (CSU). Any other prescription can only be off label. Data available from clinical trials conducted in children suggest that omalizumab is clinically effective and generally well tolerated. Given its mechanism of action, recent reports have suggested its possible clinical use in other IgE-mediated disorders, such as allergic rhinitis, food allergy, and anaphylaxis. In recent years, several studies have also investigated the possible applications of omalizumab in a number of non IgE-mediated diseases. The aim of the present review is to assess all applications of omalizumab as therapy in the pediatric population. The approved indications--allergic asthma and CSU--are reviewed. Moreover, further potential applications of omalizumab are discussed in both IgE-mediated and non-IgE-mediated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.